Aquestive Therapeutics

About Aquestive Therapeutics

Aquestive Therapeutics is a pharmaceutical company focused on advancing medicines to improve patients' lives by solving therapeutic problems and simplifying complex drug delivery methods. Their mission is to provide novel alternatives to invasive and inconvenient standard of care therapies, particularly for central nervous system (CNS) conditions and severe allergies like anaphylaxis.

Products & Services

PharmFilm® Technology:A versatile, high-performance drug delivery technology tailored for optimized absorption, bioavailability, and onset of action, used to deliver medications via oral film.

Libervant® (diazepam) Buccal Film, C-IV:An oral film medication for seizure clusters in pediatric patients, recently granted FDA Orphan Drug Exclusivity.

Anaphylm™ (epinephrine) Sublingual Film:A sublingual film under development for rapid delivery of epinephrine to treat anaphylaxis, with NDA submission planned for Q1 2025.

Licensed Commercial Medicines:A range of commercially available medicines delivered through Aquestive’s proprietary technology.

Development & Licensee Services:Services including formulation development, clinical trials, regulatory support, and commercial manufacturing for partners.

CoPacking & CDMO Services:Contract packaging and manufacturing services for oral film and secondary packaging.

Specialties

Oral Film Drug Delivery Transmucosal Drug Delivery Central Nervous System (CNS) Conditions Severe Allergy Treatment (Anaphylaxis) Innovative Drug Delivery Technologies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Royalty Financing T: - FT: Royalty Financing	A: 75000000 MR: - FA: $75 million FAN: 75000000	D: 2025-08-14 FD: 2025-08-14	1 investors
2	RT: Underwritten Offering of Common Stock T: - FT: Underwritten Offering of Common Stock	A: 85000000 MR: - FA: $85 million FAN: 85000000	D: 2025-08-14 FD: 2025-08-14	7 investors
3	RT: Public Offering T: - FT: Public Offering	A: 75000000 MR: - FA: approximately $75.0 million FAN: 75000000	D: 2024-03-25 FD: 2024-03-25	5 investors
4	RT: Public Offering T: - FT: Public Offering	A: 75000000 MR: - FA: $75 million FAN: 75000000	D: 2024-03-19 FD: 2024-03-19	3 investors
5	RT: Debt T: - FT: Debt	A: 45000000 MR: - FA: $45,000,000 FAN: 45000000	D: 2023-11-02 FD: 2023-11-02	1 investors

Royalty Financing Latest

2025-08-14

$75.0M

1 investor (Pro only)

Underwritten Offering of Common Stock 2025-08-14

$85.0M

Public Offering 2024-03-25

$75.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Daniel Barber

President and Chief Executive Officer

P

Peter Boyd

SVP, Human Resources and Information Technology

L

Lori J. Braender

Chief Legal Officer, Chief Compliance Officer and Secretary

M

Melina T. Cioffi

Senior Vice President - Regulatory Affairs

C

Cassie Jung

Chief Operating Officer

S

Sherry Korczynski

Chief Commercial Officer

View 22 more team members with Pro

Unlock Full Team Directory

Recent News